Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
1:00PMiHub NewswireFeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent
07/03/20241:06AMAlliance NewsAlliance NewsAnglo American's Australian coal mine battles three-day blazeLSE:AALAnglo American Plc
07/03/20241:06AMAlliance NewsAlliance NewsAnglo American's Australian coal mine battles three-day blazeLSE:AALAnglo American Plc
07/03/20241:04AMBusiness WireREPAY Announces Pricing of Convertible Notes OfferingNASDAQ:RPAYRepay Holdings Corporation
07/03/20241:00AMBusiness WireCTP N.V. notice of H1-2024 results
07/03/20241:00AMBusiness Wireシカモア・ツリー・キャピタル・パートナーズ「Best US Boutique CLO Manager Award」を受賞
07/03/20241:00AMGlobeNewswire Inc.Start of Day Message
07/03/20241:00AMBusiness WireElliptic Labs Signs Expansion Contract with Commercial Segment of PC Customer
07/03/20241:00AMBusiness WireBenevolentAI: Leadership Team Change
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDBIT:SANFSanofi
07/03/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneTG:SNWSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDBIT:1SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneBIT:SANFSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneBIT:1SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDTG:SNWSanofi
07/03/20241:00AMPR Newswire (US)iTRAK 5750 Intelligent Track System from Rockwell Automation Enables Faster, More Flexible Motion Across Heavier PayloadsNYSE:ROKRockwell Automation Inc
07/03/202412:28AMAlliance NewsAlliance NewsGLOBAL BRIEFING: Europe called up as Powell revives rate cut hopes
07/03/202412:19AMGlobeNewswire Inc.Yantai Exhibition Celebrates 27th Anniversary of Hong Kong's Return to Motherland
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CLAYUChavant Capital Acquisition Corporation
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBSENeuBase Therapeutics Inc
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBSENeuBase Therapeutics Inc
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ROCAUROC Energy Acquisition Corporation
07/03/202412:15AMPR Newswire (US)/C O R R E C T I O N -- Wormington & Bollinger/
07/03/202412:10AMPR Newswire (US)Persistent Acquires Starfish Associates, Strengthening its Position in AI-powered Contact Center and Unified Communications
07/03/202412:01AMPR Newswire (US)HOME AFFORDABILITY GETS TOUGHER DURING SECOND QUARTER ACROSS U.S. AS PRICES SHOOT BACK UP
07/03/202412:00AMPR Newswire (US)New Novel Illustrates What Loss Of Liberty Could Look Like